Targeted delivery of mRNA-based therapeutics to selective cells in vivo could be very valuable in the development of potent mRNA therapeutics. However, some cells such as T cells or Hematopoeitic Stem Cells (HSCs) are extremely resistant to transfection by exogenous mRNA. To date, T cell modification has required extraction of autologous T cells, expansion, and genomic editing ex vivo, which is expensive and time-consuming. In this talk, first, I will describe selective targeting of specific cells and cell subtypes using antibody-modified LNPs and delivery of mRNA interventions to those target cells. In the second part of my presentation, I will discuss the potential applications we explored with this platform such as HIV cure and mRNA-mediated CAR T cell therapy.

Targeted lipid nanoparticle platform for in vivo Delivery of mRNA therapeutics

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.